BNTX BioNTech Group: רווח למניה בשנים עשר החודשים האחרונים

BioNTech SE (BNTX) relies on external contractors for drug production, implements revolutionary mRNA technologies in oncology, and actively diversifies its asset portfolio to mitigate risks. This annual net income per share chart helps adjust positions in a timely manner during trend reversals, and -6.88 shows the current value of this parameter.

BioNTech SE is transforming windfall profits from mRNA vaccine sales into the development of personalized cancer therapies. An analysis of the company's annual revenue per share allows for an assessment of net income distributed per share over the last 12 months, which serves as an indicator of business capitalization efficiency and the issuer's ability to maintain margins during the transition to new market niches.